Journal: bioRxiv
Article Title: Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer
doi: 10.1101/2025.06.02.657429
Figure Lengend Snippet: (A/B) LNCaP cells were seeded in androgen-deprived media and treated with DHT and/or olaparib as indicated in quadruplicate for 7 d prior to assessing cell viability. (C) Normalized enrichment score for Hallmarks pathways in RNA-sequencing data from pre-ADT and post-ADT treated patient samples as described in Ref. 24. (C) Single-sample GSEA scores of cell cycle related Hallmarks pathways in matched pre-ADT and post-ADT samples. (E) LNCaP cells were seeded in full media and treated ± 5 μM palbociclib in quadruplicate for 7 d prior to assessing cell viability. (F) Cells were seeded in growth media ± 5 μM palbociclib and treated with olaparib as indicated in quadruplicate for 7 d prior to assessing cell viability. (G) Cells were seeded in androgen-deprived media ± 1 nM DHT and treated as indicated with DNA damaging chemotherapies for 7 d prior to assessing cell viability. (H) Cells were seeded in full media ± 5 μM palbociclib and treated with cisplatin as indicated for 7 d. Data are shown as mean ± SD, ***p<0.005. by one-way ANOVA with Bonferroni correction for multiple comparisons (A) or Student’s two-tailed t-test (E).
Article Snippet: Cells were seeded in 96-well plates, allowed to adhere overnight, and treated in quadruplicate with olaparib (Selleck Chemicals), rucaparib (Selleck Chemicals), AZD-5305 (MedChemExpress), enzalutamide (Selleck Chemicals), palbociclib (Selleck Chemicals), cisplatin (Fresenius Kabi), etoposide (Accord Healthcare), or doxorubicin (Sigma Aldrich) as indicated for 7 d. Cell viability was measured using the Cell Titer Glo Luminescent Cell Viability Assay (Promega) according the manufacturer’s instructions.
Techniques: RNA Sequencing, Two Tailed Test
Tocris is a verified supplier 
Tocris manufactures this product 
